NovoCure Ltd.
223 articles with NovoCure Ltd.
-
Results from STELLAR Trial of Tumor Treating Fields with Chemotherapy in Malignant Pleural Mesothelioma Published in The Lancet Oncology
10/16/2019
Novocure (NASDAQ: NVCR) today announced that results from the STELLAR trial were published in The Lancet Oncology.
-
Novocure Announces 27 Presentations at the American Society for Radiation Oncology 2019 Annual Meeting
9/9/2019
The volume of Tumor Treating Fields presentations marks a record number of abstracts for Novocure at one of the premier meetings for radiation oncologists
-
Novocure to Participate in Three Upcoming Investor Conferences
8/6/2019
Novocure announced that it will participate in three upcoming investor conferences.
-
Novocure Reports Second Quarter 2019 Financial Results and Provides Company Update
7/25/2019
Novocure reported financial results for the three and six months ended June 30, 2019, highlighting a track record of execution, strengthening financial performance and an advancing clinical pipeline.
-
CMS Establishes 2019 Monthly Fee Schedule Amount for Optune®
7/19/2019
Novocure announced the U.S Centers for Medicare & Medicaid Services has established a 2019 monthly fee schedule amount for Optune.
-
Medicare Releases Final Local Coverage Determination Providing Coverage of Optune® for Newly Diagnosed Glioblastoma
7/18/2019
Novocure announced the Medicare durable medical equipment Medicare Administrative Contractors have released a final local coverage determination providing coverage of Optune for Medicare beneficiaries with newly diagnosed glioblastoma effective September 1, 2019.
-
Novocure to Report Second Quarter 2019 Financial Results
7/2/2019
Novocure management will host a conference call and webcast to discuss its financial results for the three months ended June 30, 2019, at 8 a.m. EDT on Thursday, July 25, 2019.
-
German Institute for Quality and Efficiency in Healthcare Publishes Rapid Report Noting Optune’s Survival Benefit for Patients with Newly Diagnosed Glioblastoma
6/26/2019
National reimbursement decision for Optune® in Germany anticipated in 2020
-
Novocure to Participate in the Jefferies 2019 Global Healthcare Conference
5/24/2019
Novocure announced that Bill Doyle, Novocure’s Executive Chairman, will participate in the Jefferies 2019 Global Healthcare Conference on June 4, 2019, in New York City.
-
Shares of NovoCure are up more than 6% in premarket trading after the company announced it won regulatory approval for its mesothelioma treatment, NovoTTF-100L System.
-
FDA Approves the NovoTTF-100LTM System in Combination with Chemotherapy for the Treatment of Malignant Pleural Mesothelioma
5/23/2019
Novocure (NASDAQ: NVCR) today announced that the U.S. Food and Drug Administration (FDA) has approved the NovoTTF-100L System in combination with pemetrexed plus platinum-based chemotherapy for the first-line treatment of unresectable, locally advanced or metastatic, malignant pleural mesothelioma (MPM). NovoTTF-100L is a non-invasive, antimitotic cancer treatment that delivers Tumor Treating Fields to the region of the tumor.
-
Medicare Issues Proposed Local Coverage Determination that Provides Coverage of Optune® for Newly Diagnosed Glioblastoma
5/10/2019
Novocure (NASDAQ: NVCR) today announced the Medicare durable medical equipment (DME) Medicare Administrative Contractors (MACs) have issued a proposed local coverage determination (LCD) that provides coverage of Tumor Treating Fields, or Optune, for newly diagnosed glioblastoma (GBM)
-
Novocure Reports First Quarter 2019 Financial Results and Provides Company Update
5/2/2019
Quarterly net revenues of $73.3 million, representing 41 percent growth versus the first quarter 2018 and 5 percent growth versus the fourth quarter 2018
-
Novocure Announces the International Journal of Radiation Oncology, Biology, Physics Publishes Data Demonstrating Higher Doses of Tumor Treating Fields Improved Survival of Newly Diagnosed Glioblastoma Patients
4/30/2019
The study provides a definition for Tumor Treating Fields dose and sets a framework for future work on Tumor Treating Fields dosimetry and treatment planning
-
Novocure Publishes 2018 Annual Report Featuring Company’s Vision, Mission and Values
4/15/2019
Novocure’s mission and values support its overarching patient-forward vision to make a difference in cancer
-
Inaugural AACR-Novocure Tumor Treating Fields Research Grant Recipients Announced at AACR Annual Meeting 2019
4/3/2019
The recipients of the AACR-Novocure Tumor Treating Fields research grants were announced on April 2 at the American Association for Cancer Research Annual Meeting 2019 in Atlanta.
-
Novocure to Report First Quarter 2019 Financial Results
4/2/2019
Novocure announced that it will report financial results for the first quarter 2019 on Thursday, May 2, 2019, before the U.S. financial markets open.
-
Novocure Initiates Phase 3 Pivotal Trial in Recurrent Ovarian Cancer
3/22/2019
INNOVATE-3 will test the efficacy of Tumor Treating Fields combined with paclitaxel in patients with recurrent, platinum-resistant ovarian cancer
-
BioSpace Movers and Shakers: March 22
3/22/2019
Biotech and pharma companies make appointments to strengthen executive teams, with moves at Sanofi, Forma, Orchard, CLSA, Sangamo, and more. -
Novocure’s Chief Science Officer Retires after 17 Years of Service
3/21/2019
Novocure (NASDAQ: NVCR) today announced the retirement of Dr. Eilon Kirson, Novocure’s Chief Science Officer and Head of Research and Development, effective May 1, 2019.